Keyword: Verzenio (abemaciclib)
After Eli Lilly lowered its sales and earnings projections, analysts demanded details about new products—including migraine drug Emgality.
NICE initially told Eli Lilly that its breast cancer drug Verzenio wasn't cost-effective. So Lilly dished up a price break—and it worked.
Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.
Eli Lilly may have found one way to raise some quick cash to pour into its portfolio of growth prospects.
Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.
A new look at cancer survivors' media habits shows that where they get data and to what degree they value it depends on when they were diagnosed.
A pile of evidence for CDK 4/6 cancer drugs hasn’t yet persuaded some physicians to try the meds, but Pfizer's going all out to change their minds.
Lilly did not make a plausible case that its drug is more cost-effective than other CDK 4/6 inhibitors, England's drug-price watchdog said.
Lilly launched a new metastatic breast cancer push, in partnership with actress Mira Sorvino and "Good Morning America," with a televised yoga class.